ANTILEUKEMIC ACTIVITY OF THE TYROSINE KINASE INHIBITOR BVT II plus /- CYTARABINE OR DAUNORUBICIN IN ACUTE MYELOID LEUKEMIA

被引：0
|
作者：
Eriksson, A. [1 ]
Hassan, S. Bashir [1 ]
Hoglund, M. [1 ]
Larsson, R. [1 ]
Lindhagen, E. [1 ]
Aleskog, A. [1 ]
Fohlenhag, K. [2 ]
Jensen, A. Jenmalm [2 ]
Lehmann, F. [2 ]
Lothgren, A. [2 ]
Parrow, V. [2 ]
机构：
[1] Uppsala Univ, Uppsala, Sweden
[2] Biovitrum AB, Discovery Res, Stockholm, Sweden
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2008年 / 93卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0290
引用
收藏
页码：118 / 118
页数：1
相关论文
共 50 条
  • [41] Unfolding tyrosine kinase inhibitor sensitivity in chronic myeloid leukemia
    Perrotti, Danilo
    Neviani, Paolo
    CELL CYCLE, 2012, 11 (23) : 4300 - 4301
  • [42] Chronic Myeloid Leukemia—the Promise of Tyrosine Kinase Inhibitor Discontinuation
    Ravi Kishore Narra
    Kathryn E. Flynn
    Ehab Atallah
    Current Hematologic Malignancy Reports, 2017, 12 : 415 - 423
  • [43] Tailoring Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia
    Mauro, Michael J.
    CANCER CONTROL, 2009, 16 (02) : 108 - 121
  • [44] Tyrosine Kinase Inhibitor Sequencing in Patients with Chronic Myeloid Leukemia
    Tiribelli, Mario
    Eskazan, Ahmet Emre
    ONCOLOGY AND THERAPY, 2019, 7 (02) : 95 - 100
  • [45] Precision tyrosine kinase inhibitor dosing in chronic myeloid leukemia?
    Saglio, Giuseppe
    Fava, Carmen
    Gale, Robert Peter
    HAEMATOLOGICA, 2019, 104 (05) : 862 - 864
  • [46] Predictors of tyrosine kinase inhibitor treatment for chronic myeloid leukemia
    Cole, Ashley L.
    Wood, William A.
    Muluneh, Benyam
    Lund, Jennifer L.
    Lafata, Jennifer Elston
    Dusetzina, Stacie B.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2018, 27 : 104 - 105
  • [47] Cost-Effectiveness of Liposomal Cytarabine-Daunorubicin (CPX-351) Compared to Conventional Cytarabine-Daunorubicin Chemotherapy in Acute Myeloid Leukemia
    Bewersdorf, Jan Philipp
    Goshua, George
    Patel, Kishan K.
    Shallis, Rory M.
    Podoltsev, Nikolai
    Huntington, Scott F.
    Zeidan, Amer M.
    BLOOD, 2021, 138
  • [48] Liposomal encapsulated cytarabine and daunorubicin (CPX-351) for older patients with acute myeloid leukemia
    Asghari, Hannah
    Lancet, Jeffrey
    LEUKEMIA & LYMPHOMA, 2020, 61 (06) : 1305 - 1312
  • [49] Cost-effectiveness of liposomal cytarabine/daunorubicin in patients with newly diagnosed acute myeloid leukemia
    Bewersdorf, Jan Philipp
    Patel, Kishan K.
    Goshua, George
    Shallis, Rory M.
    Podoltsev, Nikolai A.
    Huntington, Scott F.
    Zeidan, Amer M.
    BLOOD, 2022, 139 (11) : 1766 - 1770
  • [50] ALVOCIDIB SYNERGIZES WITH CYTARABINE AND DAUNORUBICIN (7+3) IN PRECLINICAL MODELS OF ACUTE MYELOID LEUKEMIA
    Kim, W.
    Haws, H.
    Mangelson, R.
    Peterson, P.
    Whatcott, C.
    Siddiqui-Jain, A.
    Weitman, S.
    Bearss, D.
    Warner, S.
    HAEMATOLOGICA, 2017, 102 : 370 - 370
12345